We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

12 hedge funds and large institutions have $142K invested in Altamira Therapeutics Ltd in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

14% less funds holding

Funds holding: 14 → 12 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

77% less capital invested

Capital invested by funds: $607K → $142K (-$465K)

Holders
12
Holders Change
-2
Holders Change %
-14.29%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
6
Calls
$19K
Puts
–
Net Calls
+$19K
Net Calls Change
-$69K

Top Buyers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
+$22.6K
2
TRCT
Tower Research Capital (TRC)
New York
+$18.4K
3
UBS Group
UBS Group
Switzerland
+$18.1K
4
Morgan Stanley
Morgan Stanley
New York
+$14.5K
5
VF
Virtu Financial
New York
+$10.3K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$198K
2
BlackRock
BlackRock
New York
-$67K
3
BFM
Boothbay Fund Management
New York
-$34K
4
HF
HRT Financial
New York
-$19K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$14.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
1
Group One Trading
Illinois
$39K +$22.6K +70 +53%
IC
2
Ikarian Capital
Texas
$36K -$198K -612 -77%
Morgan Stanley
3
Morgan Stanley
New York
$13K +$14.5K +45 +214%
UBS Group
4
UBS Group
Switzerland
$13K +$18.1K +56 +622%
TRCT
5
Tower Research Capital (TRC)
New York
$11K +$18.4K +57 New
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$9K -$14.5K -45 -49%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$9K – – –
VF
8
Virtu Financial
New York
$6K +$10.3K +32 New
VPIM
9
Vanguard Personalized Indexing Management
California
$5K +$8.39K +26 New
CG
10
Cutler Group
California
$1K +$968 +3 +60%
BlackRock
11
BlackRock
New York
– -$67K -154 Closed
BFM
12
Boothbay Fund Management
New York
– -$34K -77 Closed
HF
13
HRT Financial
New York
– -$19K -44 Closed
1832 Asset Management
14
1832 Asset Management
Ontario, Canada
– -$1K -3 Closed
GI
15
Gradient Investments
Minnesota
– -$1K -3 Closed
Osaic Holdings
16
Osaic Holdings
Arizona
– +$323 +1 New

CYTO Hedge Fund Activity: Q2 2022 in Review

12 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2022, worth a combined $142K — down 77% from $607K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CYTO and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was Group One Trading, adding an estimated $22.6K. The largest seller was Ikarian Capital, cutting an estimated $198K.

  • 12 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2022, down from 14 in Q1 2022.
  • Funds reported $142K of Altamira Therapeutics Ltd stock for Q2 2022, down 77% quarter-over-quarter.
  • 4 funds opened new Altamira Therapeutics Ltd positions in Q2 2022 and 6 closed out, a net change of -2 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q2 2022 was Group One Trading, an estimated $22.6K added.
  • The largest Altamira Therapeutics Ltd seller in Q2 2022 was Ikarian Capital, an estimated $198K sold.

Based on aggregated 13F filings for Q2 2022.